Follow the EQL Pharma AB share price and the full insider trade history of the company, a listed issuer based in Finland. Shares are quoted on the FI market, under the authority of FIN-FSA. Operating in the Health Care sector, EQL Pharma AB has logged 14 reports. Market capitalisation: €756m. The latest transaction was disclosed on 19 August 2026 (Purchase). Among the most active insiders: Axel Schörling. All data is free.
14
Insider Decl.
n/a
Thresholds
€454,844
9 ops.
Buy Volume
€118,679
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate EQL Pharma AB Strong Buy (bullish), based on 1 analysts. Average price target: SEK 47.50.
37Σ signal
Buys €454,844€118,679 Sells
Fundamental score
Ranked 22,847 of 29,057 companies
31.7
score / 100
Value
30
Quality
33
FCF yld-4.9%
Earn yld1.6%
EV/EBITDA18.6x
ROE-1.1%
Gross mgn38%
Net mgn2.9%
Debt/EBITDA6.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
3,542 shares@ €6.0020.0028% mcap100.0% of flowAktieISINISIN SE0005497732FI:A003N308-1
14 of 14 declarations
About EQL Pharma AB
EQL Pharma AB is a company focused on the development and commercialization of generic drugs and pharmaceutical products. It is listed on the Stockholm Stock Exchange (XSTO).